<DOC>
	<DOC>NCT00751738</DOC>
	<brief_summary>This is an open-label, multi-center, long-term, (open-ended) safety study with 125 mg per day of azimilide in patients who completed protocol 2000098.</brief_summary>
	<brief_title>Long Term Safety of 125 mg Per Day of Oral Azimilide in Patients With Implantable Cardioverter Defibrillator (ICDs)</brief_title>
	<detailed_description />
	<mesh_term>Azimilide</mesh_term>
	<criteria>patients who completed at least 12 months on study 2000098 before inclusion in this study breast feeding or plan to become pregnant used ticlopidine were taking Class I or other Class III drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>